Leadership

Target ALS Team

We have built a team that brings together a unique mix of clinical, scientific, business, and philanthropic expertise.

Manish Raisinghani

Manish Raisinghani

M.B.B.S., Ph.D., Chief Executive Officer

Kenneth Devaney

Kenneth Devaney

Chief Operations Officer

Jesse Bailey

Jesse Bailey

Chief Development Officer

Steve Schonberg

Steve Schonberg

Director of Communications

Burhan Siddiqui

Burhan Siddiqui

Finance Associate

Read Our Story

Foundation Advisors

Our Foundation Advisors guide the Target ALS administration in ensuring that we are following best-in-class scientific approaches in our work, and they keep us closely connected to the latest developments in the field.

Chris Henderson

Chris Henderson

Ph.D., Chief Advisor, Biogen

Leonard Petrucelli

Leonard Petrucelli

Ph.D., Chief Scientific Advisor

Board Members

The Target ALS Board of Directors sets overall policy and provides guidance to the Foundation’s executive leadership team. To ensure we craft truly ground-breaking strategies to foster collaboration and accelerate drug discovery and development, we have recruited a renowned, passionate group of pioneering academic leaders, pharmaceutical and biotech executives, patients and their family members and visionary philanthropists.

Daniel L. Doctoroff

Daniel L. Doctoroff

Founder and Board Chair

John Dunlop

John Dunlop

Amgen, Inc., Vice President of Research

Zach Hall

Zach Hall

Ph.D., National Institute of Neurological Disorders and Stroke (Former Director)

Story Landis

Story Landis

Ph.D., National Institute of Neurological Disorders and Stroke

Mike Poole

Mike Poole

M.D., Biomatics Capital

Jeff Rothstein

Jeff Rothstein

M.D., Ph.D., Johns Hopkins University

Stacie Weninger

Stacie Weninger

Ph.D., F-Prime Biomedical Research Initiative

Independent Review Committee

To ensure that Target ALS funds the top ideas in the field in an objective manner, all grant-making decisions are made by an Independent Review Committee (IRC). The IRC is comprised of investigators from industry, academia and non-profit organizations who represent expertise from different but complementary areas of science. To avoid a conflict of interest, members of the IRC are neither allowed to apply for, nor receive funding from Target ALS. The committee is chaired by Robert Miller, Ph.D., George Washington University.

Robert Miller

Robert Miller

Ph.D., George Washington University

Michael Ahlijanian

Michael Ahlijanian

Ph.D., ANI Consulting, LLC.

Manzoor Bhat

Manzoor Bhat

Ph.D., M.S., University of Texas Health Science Center, San Antonio

Moses Chao

Moses Chao

Ph.D., New York University

Kurt Fischbeck

Kurt Fischbeck

M.D., National Institutes of Health

Jonathan Glass

Jonathan Glass

M.D., Emory University

Zaven Kaprielian

Zaven Kaprielian

Project Chief Scientific Officer, Dementia Discovery Fund U.S.

Jim Kupiec

Jim Kupiec

M.D., ProMIS Neurosciences, Inc.

Lynne Maquat

Lynne Maquat

Ph.D., University of Rochester Medical Center

Jere Meredith, Jr.

Jere Meredith, Jr.

Ph.D., Arvina

Robert Mays

Robert Mays

Ph.D., Athersys

Richard Olson

Richard Olson

Ph.D., Bristol-Myers Squibb

Mahendra Rao

Mahendra Rao

M.D., Ph.D. InSTEM

Rajiv Ratan

Rajiv Ratan

M.D., Ph.D., Cornell University

Ian Reynolds

Ian Reynolds

Ph.D., Rewind Therapeutics

Eric Schaeffer

Eric Schaeffer

Ph.D., Johnson & Johnson

Holly Soares

Holly Soares

Ph.D., Head of Precision Medicine, VP at Pfizer

Leslie Thompson

Leslie Thompson

Ph.D., Codiak Biosciences

Ajay Verma

Ajay Verma

M.D., Ph.D., United Neuroscience

Frank Walsh

Frank Walsh

Ph.D., Ossianix

Andrew Wood

Andrew Wood

Ph.D., CHDI

Conflict of Interest Committee

The Target ALS Conflict of Interest Committee ensures that the Independent Review Committee has no stake in projects selected and addresses any conflict of interest issues raised by the research community.

The committee is chaired by Zach Hall, Ph.D., Former Director of National Institute of Neurological Disorders and Stroke.

Zach Hall

Zach Hall

Ph.D., National Institute of Neurological Disorders and Stroke (Former Director)

Daniel L. Doctoroff

Daniel L. Doctoroff

Founder and Board Chair

Robert Miller

Robert Miller

Ph.D., George Washington University

Neil Shneider

Neil Shneider

M.D., Ph.D., Columbia University

James Treanor

James Treanor

Ph.D., ADRx